[Refractory schizophrenia]
- PMID: 18157433
- DOI: 10.1590/s1516-44462007000600002
[Refractory schizophrenia]
Abstract
Objective: The aim of the present paper is to review the various aspects of refractory schizophrenia regarding issues such as definitions, clinical aspects, psychobiological correlates, pharmacological and non-pharmacological treatment options and predictors of treatment response.
Method: Medline search as well as articles of the authors.
Results and conclusions: Refractory schizophrenia affects at least one third of patients with schizophrenia and the best evidence shows that is monotherapy with clozapine remains the mainstay for the treatment of such condition. Antipsychotic polipharmacy is not supported by current evidence and recent clinical trials have shown that clozapine augmentation with antipsychotics has no benefit over placebo.
Similar articles
-
Augmentation strategies of clozapine with antipsychotics in the treatment of ultraresistant schizophrenia.Clin Neuropharmacol. 2006 Jan-Feb;29(1):28-33. doi: 10.1097/00002826-200601000-00009. Clin Neuropharmacol. 2006. PMID: 16518132 Review.
-
Augmentation strategies in clozapine-resistant schizophrenia.CNS Drugs. 2005;19(10):843-72. doi: 10.2165/00023210-200519100-00004. CNS Drugs. 2005. PMID: 16185094 Review.
-
A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.J Psychiatry Neurosci. 2009 Nov;34(6):433-42. J Psychiatry Neurosci. 2009. PMID: 19949719 Free PMC article. Review.
-
Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.JAMA Psychiatry. 2019 May 1;76(5):499-507. doi: 10.1001/jamapsychiatry.2018.4320. JAMA Psychiatry. 2019. PMID: 30785608 Free PMC article.
-
Polypharmacy in schizophrenia.Curr Opin Psychiatry. 2010 Mar;23(2):103-11. doi: 10.1097/YCO.0b013e3283366427. Curr Opin Psychiatry. 2010. PMID: 20051861 Review.
Cited by
-
Pharmacogenetic Analysis of Functional Glutamate System Gene Variants and Clinical Response to Clozapine.Mol Neuropsychiatry. 2017 Feb;2(4):185-197. doi: 10.1159/000449224. Epub 2016 Oct 12. Mol Neuropsychiatry. 2017. PMID: 28277565 Free PMC article.
-
Use of clozapine for the treatment of schizophrenia: findings of the 2006 research on the china psychotropic prescription studies.Clin Psychopharmacol Neurosci. 2012 Aug;10(2):99-104. doi: 10.9758/cpn.2012.10.2.99. Epub 2012 Aug 31. Clin Psychopharmacol Neurosci. 2012. PMID: 23430459 Free PMC article.
-
Measuring Users' Receptivity Toward an Integral Intervention Model Based on mHealth Solutions for Patients With Treatment-Resistant Schizophrenia (m-RESIST): A Qualitative Study.JMIR Mhealth Uhealth. 2016 Sep 28;4(3):e112. doi: 10.2196/mhealth.5716. JMIR Mhealth Uhealth. 2016. PMID: 27682896 Free PMC article.
-
Expression of Dopamine D1-4 and Serotonin 5-HT1A-3A Receptors in Blood Mononuclear Cells in Schizophrenia.Front Psychiatry. 2021 Mar 10;12:645081. doi: 10.3389/fpsyt.2021.645081. eCollection 2021. Front Psychiatry. 2021. PMID: 33776821 Free PMC article.
-
m-RESIST, a Mobile Therapeutic Intervention for Treatment-Resistant Schizophrenia: Feasibility, Acceptability, and Usability Study.JMIR Form Res. 2023 Jun 30;7:e46179. doi: 10.2196/46179. JMIR Form Res. 2023. PMID: 37389933 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical